安徽黄山胶囊股份有限公司 董事会议事规则 中国·安徽 安徽黄山胶囊股份有限公司 董事会议事规则 安徽黄山胶囊股份有限公司 董事会议事规则 第一章 总则 第一条 为完善安徽黄山胶囊股份有限公司（以下简称"公司"）法人治 理结构，规范董事会及其成员的组织和行为，保证董事会议事程序及其决议的 合法性，确保董事会高效运作和科学决策，维护公司、股东、债权人及公司职 工的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司治理准则》《深圳证券交易所股票上市规则》（以下简称"《上市 规则》"）《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规 范运作》等法律、法规、规范性文件及《安徽黄山胶囊股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，并结合公司的实际情况，制定本规则。 第二条 公司设立董事会，由股东大会选举产生，受股东大会的委托，负 责经营管理公司的法人财产，对股东大会负责。 第三条 本规则是董事会及其成员组织和行为的基本准则。 第二章 董事会的性质、组成和职权 第四条 董事会是公司权力机构的执行机构，对外代表公司，对内执行股 东大会决议。 第五条 董事会对股东大会负责并 ...

安徽黄山胶囊股份有限公司 2023 年度监事会工作报告 2023 年，公司监事会依照《公司法》、《证券法》、《公司章程》及《安徽黄山 胶囊股份有限公司监事会议事规则》等有关法律法规及规定，恪尽职守、勤勉尽责的履 行各项职责，通过列席公司董事会、股东大会，直接听取公司各项工作报告与财务报告， 定期与公司高级管理人员进行沟通、查阅相关资料，对公司的决策程序、内部控制制度 的建立与执行情况以及公司董事、高级管理人员的履职情况进行监督，有效发挥了监事 会职能，保障了公司规范运作。现将 2023 年度监事会工作情况报告如下： 一、监事会会议召开情况 报告期内，公司监事会依法对公司财务制度和财务管理情况进行了检查，对各定期 报告发表了意见。监事会认为：公司财务体系完善，制度健全，定期财务报告真实、准 确、完整地反映了公司的财务状况、经营成果和现金流量，不存在虚假记载、误导性陈 述或重大遗漏。 （三）审核公司内部控制评价报告 报告期内，公司监事会共召开了 3 次会议，会议情况如下： （一）第五届监事会第二次会议于 2023 年 4 月 26 日在公司会议室召开，审议通过 了《关于公司 2022 年度监事会工作报告的议案》、 ...

Financial Performance - The company's revenue for Q3 2023 was ¥99,824,742.43, representing a year-over-year increase of 6.59%[5] - Net profit attributable to shareholders for Q3 2023 was ¥17,142,218.34, up 3.37% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,282,951.74, an increase of 13.01% year-over-year[5] - Total operating revenue for the current period reached CNY 355,505,976.10, an increase of 18.0% compared to CNY 301,178,173.56 in the previous period[21] - Operating profit for the current period was CNY 60,929,217.57, up 15.0% from CNY 52,708,862.18 in the previous period[22] - Net profit attributable to shareholders of the parent company was CNY 55,117,552.98, representing a 14.0% increase from CNY 48,099,259.10 in the previous period[22] - The company reported a total comprehensive income of CNY 55,528,297.21, an increase from CNY 48,522,337.05 in the previous period[22] - The basic and diluted earnings per share for the current period were both CNY 0.18, up from CNY 0.16 in the previous period[22] Assets and Liabilities - Total assets at the end of Q3 2023 reached ¥1,108,915,261.96, reflecting a 6.86% increase from the end of the previous year[5] - Total assets as of September 30, 2023, reached CNY 1,108,915,261.96, an increase from CNY 1,037,692,058.04 at the beginning of the year, reflecting a growth of approximately 6.5%[19] - Current assets totaled CNY 719,113,903.18, up from CNY 618,271,712.89, indicating an increase of about 16.3%[18] - Total liabilities amounted to CNY 217,099,381.32, up from CNY 183,481,821.74, reflecting an increase of about 18.3%[19] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥66,775,958.30, showing a slight decrease of 0.42%[5] - Cash flow from operating activities generated a net amount of CNY 66,775,958.30, slightly down from CNY 67,058,100.52 in the previous period[23] - The company recorded a net cash inflow from investment activities of CNY 43,059,386.13, a significant improvement from a net outflow of CNY 246,780,048.91 in the previous period[23] Equity and Shareholder Information - The company's total equity attributable to shareholders increased to ¥891,156,479.42, a rise of 4.38% from the previous year[5] - The total equity attributable to shareholders of the parent company was CNY 891,156,479.42, up from CNY 853,758,112.73, representing a growth of about 4.4%[20] - The company's retained earnings reached CNY 448,335,317.32, compared to CNY 411,140,417.21, indicating an increase of approximately 9%[20] - The number of common shareholders at the end of the reporting period was 24,170[15] - The largest shareholder, Shandong Lutai Holdings, holds a 29.99% stake, totaling 89,699,541 shares[15] Investment and Expenses - The company reported a significant increase in investment cash flow, with a net increase of ¥28,983,940.00, up 117.45% year-over-year[12] - Research and development expenses for the current period were CNY 10,532,652.54, compared to CNY 10,418,005.92 in the previous period, indicating a stable investment in innovation[21] - The total operating costs increased to CNY 298,997,243.66, up 15.8% from CNY 258,188,846.27 in the previous period[21] Other Information - Cash and cash equivalents increased by ¥30,494,050.00, a growth of 151.22% compared to the same period last year[13] - Cash and cash equivalents at the end of the period totaled CNY 421,893,061.41, significantly up from CNY 142,238,131.71 in the previous period[24] - The company experienced a 100% increase in long-term loans, amounting to ¥1,071,580.00, primarily due to new loans for a digital workshop project[10] - The basic earnings per share for Q3 2023 remained stable at ¥0.06, with a year-to-date increase of 12.50%[5] - The third quarter report has not been audited[25] - The company will implement new accounting standards starting from 2023[25] - The board meeting was held on October 11, 2023[26]

证券代码：002817 证券简称：黄山胶囊 公告编号：2023-029 安徽黄山胶囊股份有限公司 2.审议通过《关于制定<会计师事务所选聘制度>的议案》 会议以 3 票同意，0 票反对，0 票弃权，审议通过了《关于制定<会计师事务 所选聘制度>的议案》。《会计师事务所选聘制度》详见公司指定信息披露媒体巨 潮资讯网（http://www.cninfo.com.cn）。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届监事会第四次会议 通知于2023年9月25日以电子邮件及电话等方式向公司全体监事发出，会议于 2023年10月11日上午11:00在公司一楼会议室召开。本次会议应到监事3人，实到 监事3人。列席本次会议的有董事会秘书张文政先生。会议由监事张新华先生主 持，本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定。 二、监事会会议审议情况 1.审议通过《2023 年第三季度报告》 会议以3票同意，0票反对，0票弃权，审议通过了《2023年第三季度报 ...

安徽黄山胶囊股份有限公司会计师事务所选聘制度 第一章 总则 第一条 为进一步规范安徽黄山胶囊股份有限公司（以 下简称"公司"）选聘（含续聘、改聘，下同）会计师事务 所的行为，切实维护股东利益，提高财务信息质量，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《国 有企业、上市公司选聘会计师事务所管理办法》（以下简称 "《选聘办法》"）以及《安徽黄山胶囊股份有限公司章程》 （以下简称"公司章程"）的有关规定，特制定本制度。 第二条 公司选聘执行年报审计业务的会计师事务所对 财务会计报告、内部控制等发表审计意见、出具审计报告， 应当遵照本制度，履行选聘程序。选聘其他专项审计业务的 会计师事务所，视重要性程度可参照本制度执行。 第三章 选聘会计师事务所程序 第三条 公司选聘会计师事务所应当先经董事会审计委 员会（以下简称"审计委员会"）审核同意，再经董事会、 股东大会审议，不得在董事会、股东大会审议决定前聘请会 计师事务所开展审计业务。 第四条 持有公司 5%以上股份的股东、实际控制人不得 在公司董事会、股东大会审议决定前指定会计师事务所，不 得干预审 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2023-028 安徽黄山胶囊股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届董事会第四次会议 通知于 2023 年 9 月 25 日以电子邮件及电话等方式向公司全体董事发出，会议于 2023 年 10 月 11 日上午 9:00 在公司办公楼一楼会议室以现场结合通讯的方式召 开。本次会议应到董事 7 名，实到董事 7 名。公司监事和高级管理人员列席了会 议。会议由董事长李合军先生主持。本次会议的通知、召集、召开、审议、表决 程序均符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定， 会议形成的决议合法、有效。 二、董事会会议审议情况 1、第五届董事会第四次会议决议。 特此公告。 1、审议通过《2023 年第三季度报告》 会议以 7 票同意，0 票反对，0 票弃权，审议通过了《2023 年第三季度报告》。 《2023 年第三季度报告》详见公司指定信息披露媒体《证券时报》、《 ...

证券代码:002817 证券简称:黄山胶囊 | --- | --- | --- | |----------------|-------------------------------------|------------------| | 投资者关系活动 | 特定对象调研 | 分析师会议 | | 类别 | 媒体采访 | 业绩说明会 | | | 新闻发布会 | 路演活动 | | | 现场参观 | | | | ☑ 其他(2023 | | | 参与单位名称及 | 参加 2023 | | | 人员姓名 | 资者 | | | 时间 | 2023 年 9 月 12 日(周二 | 下午 15:30~17:30 | | 地点 | 公司通过全景网"投资者关系互动平台"( | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、财务总监刘清科 | | | 员姓名 | 2、副总经理、董事会秘书张文政 | | | | 3、证券事务代表汪宝珍 | | 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复: 1、鲁泰作为大股东收购一年来做了哪些工作,为什么股价一直 低迷。 尊敬的投 ...

证券代码:002817 证券简称:黄山胶囊 公告编号:2023-026 安徽黄山胶囊股份有限公司 关于参加 2023 年安徽辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,安徽黄山胶囊股份有限公司(以下简称 "公司")将参加由安徽证监局、安徽省上市公司协会与深圳市全景网络有限公 司联合举办的"2023 年安徽辖区上市公司投资者网上集体接待日"活动,现将相 关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 (https://rs.p5w.net),或关注微信公众号:全景财经,或下载全景路演 APP, 参与本次互动交流,活动时间为 2023 年 9 月 12 日(周二)15:30-17:30。届时 公司高管将在线就公司 2023 年半年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题,与投资者进行沟通与交 流,欢迎广大投资者踊跃参与! 特此公告! 安徽黄山胶囊股份有限公司 董 事 会 2023 年 09 月 07 日 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥255,681,233.67, representing a 23.21% increase compared to ¥207,521,874.75 in the same period last year[22]. - The net profit attributable to shareholders was ¥37,975,334.64, up 20.50% from ¥31,515,861.09 year-on-year[22]. - The net profit after deducting non-recurring gains and losses increased by 41.63%, reaching ¥34,373,001.25 compared to ¥24,268,965.07 in the previous year[22]. - The basic and diluted earnings per share rose to ¥0.13, an 18.18% increase from ¥0.11 in the same period last year[22]. - The total assets at the end of the reporting period were ¥1,074,717,678.35, a 3.57% increase from ¥1,037,692,058.04 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 2.36% to ¥873,916,302.08 from ¥853,758,112.73 at the end of the previous year[22]. - The gross profit margin for the pharmaceutical hollow capsule manufacturing industry improved to 29.95%, an increase of 2.20% from the previous year[47]. - The company reported a profit margin of approximately 14.9% for the first half of 2023, compared to 15.2% in the same period of 2022[126]. - The total comprehensive income for the first half of 2023 was ¥38,362,806.65, compared to ¥31,614,620.84 in the first half of 2022, reflecting a growth of 21.5%[126]. Cash Flow and Investments - The net cash flow from operating activities significantly decreased by 86.98%, amounting to ¥3,033,130.35 compared to ¥23,293,267.85 in the same period last year[22]. - Cash and cash equivalents increased by 116.98% to ¥28,418,125.31, primarily due to improved cash flow from investment activities[43]. - The net cash flow from investment activities was CNY 43,409,804.17, a turnaround from a negative CNY 170,909,163.63 in the first half of 2022[131]. - Cash inflow from investment activities totaled CNY 49,817,403.51, down 83.2% from CNY 296,870,230.61 year-on-year[131]. - Cash outflow from investment activities decreased to CNY 6,407,599.34, compared to CNY 467,779,394.24 in the previous year, a reduction of 98.6%[131]. - The net cash flow from financing activities was negative at CNY -18,211,412.10, slightly improved from CNY -19,923,044.79 in the same period last year[132]. Market and Operational Strategy - The company plans to enhance its raw material security system to adapt to market changes and maintain stable growth[30]. - The company has established a comprehensive procurement, production, and sales system to optimize operational efficiency[34]. - The company focuses on R&D, having developed advanced technologies for enteric-coated capsules and obtained several patents[39]. - The company has built a large marketing network, serving over 30 provinces and establishing partnerships with major pharmaceutical companies[38]. - The company emphasizes a customer-centric approach, offering customized marketing services to enhance client relationships[38]. - The company is actively responding to industry challenges, including drug procurement policies and rising raw material costs, to strengthen its market position[35]. - The company plans to optimize product structure and enhance market expansion efforts in response to external challenges[63]. - The company plans to expand its market presence and invest in new product development to drive future growth[138]. Risk Management - The company has outlined potential risks and corresponding measures in its management discussion section, which investors are encouraged to review[4]. - The company faced risks related to policy regulation, raw material price fluctuations, product price reductions, and human resources[63][64]. - The company plans to continue monitoring and adjusting its credit loss provisions based on economic forecasts and historical data[182]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,705[103]. - The largest shareholder, Shandong Lutai Holding Group, holds 29.99% of the shares, totaling 89,699,541 shares[104]. - The second-largest shareholder, Yu Chunming, holds 8.06% with 24,103,274 shares[104]. - The company has not undergone any significant changes in shareholding structure during the reporting period[101]. - The company has not reported any changes in the actual controller during the reporting period[107]. Compliance and Governance - The report indicates that there are no significant changes in the company's accounting policies or financial reporting standards during the reporting period[23]. - The financial statements for the first half of 2023 were approved by the board of directors on August 18, 2023[149]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[150]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position, operating results, and cash flows accurately[152]. Environmental and Social Responsibility - The company has implemented a unified management system for environmental protection and established responsibility targets for its environmental work[75]. - The company actively participates in social welfare activities, including voluntary blood donation and support for disadvantaged employees[76].

证券代码：002817 证券简称：黄山胶囊 公告编号：2023-023 安徽黄山胶囊股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届监事会第三次会议 通知于2023年8月8日以电子邮件及电话等方式向公司全体监事发出，会议于2023 年8月18日上午11:00在公司一楼会议室召开。本次会议应到监事3人，实到监事3 人。列席本次会议的有董事会秘书张文政先生。会议由监事张新华先生主持，本 次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定。 二、监事会会议审议情况 1.审议通过《2023 年半年度报告及摘要》。 具体内容详见公司于 2023 年 8 月 19 日在指定信息披露媒体《证券时报》、 《上海证券报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn） 披露的《2023 年半年度报告摘要》（公告编号：2023-021）和《2023 年半年度 报告》。 表决结果：同意 3 票，反 ...